Repare Therapeutics Inc. entered into a definitive asset purchase agreement with Gilead Sciences, Inc. to sell its polymerase theta (Polθ) ATPase inhibitor, RP‑3467. The deal provides Repare with up to $30 million in total consideration, consisting of a $25 million upfront payment and a potential $5 million milestone payment tied to technology‑transfer milestones and development milestones achieved by Gilead.
The transaction marks Repare’s third and most significant portfolio transaction of 2025 and signals a strategic pivot toward monetizing non‑core assets while concentrating resources on its remaining clinical programs. Repare reported a net loss of $30.1 million in the first quarter of 2025, underscoring a high burn rate that the $30 million cash infusion is expected to reduce, thereby extending the company’s runway for ongoing development.
The cash received from Gilead increases Repare’s liquidity, which in turn raises the estimated per‑share payout in the pending acquisition by XenoTherapeutics. The upfront payment lifts the projected payout to approximately $2.20 per common share, up from the earlier estimate of $1.82, improving shareholder value in the transaction.
Gilead’s interest in RP‑3467 reflects its broader oncology strategy, which focuses on synthetic‑lethality approaches. RP‑3467 is a first‑in‑class Polθ ATPase inhibitor that has shown preclinical activity in homologous‑recombination‑deficient tumors and is being evaluated in the POLAR Phase 1 trial, both alone and in combination with the PARP inhibitor olaparib. The asset complements Gilead’s existing oncology pipeline and expands its portfolio of targeted therapies for patients with DNA‑damage‑repair deficiencies.
Steve Forte, President, CEO, and CFO of Repare, said the deal “provides a significant cash infusion that will support our core clinical programs and accelerate our focus on the most promising assets.” He added that the transaction “represents the third and most significant portfolio transaction for Repare this year.”
Investors responded positively to the announcement, reflecting confidence in Repare’s ability to generate liquidity through strategic asset sales and in Gilead’s commitment to expanding its synthetic‑lethality oncology portfolio.
The sale of RP‑3467 to Gilead is a material event that strengthens Repare’s financial position, enhances shareholder value through the Xeno acquisition, and bolsters Gilead’s oncology pipeline with a promising synthetic‑lethality target.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.